This article is more than 5 years old. Information may no longer be current.

Surveyed gastroenterologists likely to prescribe Entyvio to IBD patients

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Most surveyed gastroenterologists were familiar with vedolizumab as an FDA-approved treatment alternative for patients with inflammatory bowel disease and anticipated prescribing it to their patients within 1 year, according to a Decision Resources Group press release.

“The majority of surveyed US gastroenterologists are excited about Takeda Pharmaceutical’s Entyvio, and welcome the agent with a different mechanism of action,” Adi Reske, PhD, Decision Resources Group analyst, said in the release. “Within the next year, we anticipate an increase in Entyvio’s use, primarily among ulcerative colitis and Crohn’s disease [tumor necrosis factor]-refractory patients.

“Until long-term safety data are available, PML [progressive multifocal leukoencephalopathy] will remain a concern among some gastroenterologists, constraining Entyvio use as a first-line biologic.”

Reske’s research consisted of an online survey of 72 gastroenterologists and qualitative interviews with 10 respondents, the release said. In addition to familiarity and prescription expectancy, the majority of respondents agreed there is a need for alternate therapies, with less than 50% satisfied with currently available treatments for moderate to severe IBD. Furthermore, most respondents concurred that PML risk associated with vedolizumab is a concern, while the most commonly cited advantage was its different mechanism of action. Those surveyed also agreed that TNF-refractory IBD patients are the ideal candidates, making infliximab (Remicade, Janssen Biotech) and adalimumab (Humira, AbbVie) likely to remain first-line biologics, the release said.

“High opportunity exists for emerging therapies in the [IBD] disease market,” Reske said. “Improved efficacy in the acute and maintenance setting, long-term safety and more convenient dosing formulations are the highly desired attributes for products in development for UC and CD.”